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This study aims to assess the perceived practice and barriers towards the provision of asthma management 
services among urban community pharmacists in Selangor, Malaysia. The study also highlights both 
pharmacist and patient-related barriers in asthma counseling. One hundred fifty urban community 
pharmacists in Selangor, Malaysia, were randomly selected and recruited for the present cross sectional 
baseline study. Previous studies have explored pharmacists’ perception on their roles in asthma management 
in different parts of the world. The data was collected through self-explanatory questionnaires (containing 47 
items). The extracted data from the completed questionnaires were analyzed descriptively and inferentially 
using Statistical Package for Social Science (SPSS) version 19. Results showed that pharmacists perceived 
their roles in asthma management along three major dimensions: ‘patient self-management’, ‘medication 
use’ and ‘asthma control’, mean (±SD) score of the perception towards asthma management was 99.29 ± 
4.58 over a maximum possible score of 110 with 90.26%. There were significant differences between the 
pharmacy education level and perceived practice of asthma management while there were insignificant 
differences between age, gender, ethnicity, number of practicing year and perceived practice of asthma 
management among respondents. Most common barriers towards asthma counselling including lack of 
time, lack of asthma knowledge, lack of counselling space and cost of asthma drugs. Conclusively, urban 
community pharmacists in Selangor, Malaysia, demonstrate good perceived practice of better management 
of asthma with multidimensional dimensional role against in disease care.
Keywords: Asthma. Perceived practive. Treatment barriers. Community pharmacists. Disease 
management.
INTRODUCTION
Over the past years, it has been suggested through 
research that suboptimal drug therapy may be one of the 
most prevalent components of medical care that causes 
preventable patient injury (Mann et al., 2014). In addition 
to the symptoms of the disease itself, Patients with chronic 
diseases such as asthma often experience a considerable 
physical, emotional, and social burden (Boehmer et al., 
2016; Meltzer, 2016). For many chronic conditions, poor 
patient compliance with prescribed medications and other 
aspects of medical treatment can adversely affect the 
treatment outcome (Loghman-Adham, 2003).
Regardless of the medical condition, non-compliance 
persists across socioeconomic and geographic boundaries 
(Vardeman-Winter, 2016). Poor compliance occurs in 
both acute and chronic therapy and approximates 50% 
for long-term therapies for chronic medical conditions 
(Hylands-White, Duarte, Raphael, 2017). Recent studies 
have demonstrated that patients do not always adhere to 
treatment regimens for a number of reasons (Vietri et al., 
2016) including breakdown in communication between 
health professionals and patients (Dawson-Rose et al., 
2016).
Community pharmacists have expanded their roles 
in recent years to include giving health care advice to 
people with acute and chronic illnesses (Butler et al., 
2017). Community pharmacists are in a unique position 
to help patients managing chronic illnesses in the light 
of their expertise, their regular interaction with patients 
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and accessibility (Bailey et al., 2016; Ogunbayo et 
al., 2017). Pharmacists have the duty of providing 
pharmaceutical care to asthmatic patients and the quality 
of care depends greatly on their attitudes and knowledge 
of pathophysiology and pharmacotherapy of the disease 
(Watkins et al., 2016; Hersberger, Messerli, 2016). Given 
the focus on improving primary-care management of 
asthma, pharmacists often represent an underutilized 
resource (Watkins et al., 2016). In developing countries, 
community pharmacies are the first point of contact 
between pharmacist and patient (Khanal et al., 2016). 
Therefore, the role of community pharmacists is vital for 
the management of chronic ailments like asthma.
When it comes to the delivery of asthma management 
services, it is appropriate that pharmacists undergo 
specialized training and recognized as experts in asthma 
(Han et al., 2016). However, without necessarily 
delivering a comprehensive and/or structured disease-
state management service, there is a wide range of 
specific interventions that pharmacists can deliver as 
part of routine practice (Patterson et al., 2016). Till 
now, no randomized studies have tested the perception 
of community pharmacists in the provision of asthma 
management among urban community pharmacists 
in Selangor, Malaysia. Therefore, this study aimed to 
assess the perceived practice and barriers toward asthma 
management among the urban community pharmacists.
SUBJECTS AND METHODS 
Study design and population 
A cross-sectional survey was conducted from 
January 5th to July 15th, 2016, in the state of Selangor, 
Malaysia. The minimum effective sample size was 
estimated to be 150 by using the online sample size 
calculator Raosoft® with a confidence interval of 95 and 
5% margin of error. Due to lack of sampling frame and 
up-to-date electronic population database, a convenient 
sampling technique was used. A total of 157 registered 
urban community pharmacists were initially approached, 
but only 153 gave signed consent for participation. 
Data from 3 participants were incomplete and therefore 
excluded from the studies. 
Data collection 
The survey was conducted by a single investigator. 
The questionnaire was adapted and designed from several 
publications with approval from the corresponding authors 
(Anderson et al., 1998; Chopra et al., 2002; McDonald, 
Gibson, 2006; Kritikos, Reddel, Bosnic-Anticevich, 
2010) and aligned with latest GINA (Global Initiative 
for Asthma) guidelines (Global Initiative for Asthma 
GINA Report, 2012). The investigator systematically 
met with the community pharmacists and explained the 
objectives of the survey. Apart from the rare cases where 
the pharmacists responded on the spot, the investigator 
was often obliged to return at a time suitable for the 
pharmacists. If the questionnaire was not filled out on 
the day of the visit, the pharmacist was requested to 
respond in front of the investigator or to schedule another 
visit. After six visits to the same pharmacy without a 
response, the respondent was excluded from the study. 
There were three parts of the questionnaire. The first part 
of the questionnaire was consisted of socio-demographic 
data, the second part of the questionnaire evaluated the 
perceived practice (n = 22 items) with three main domains 
of patients’ self-management (item number: 1,4,5,6), 
medication use (item number: 8,9,10,11,12) and asthma 
control (item number: 2,3,7,13,14,15,16,17,18,19,20,
21,22), (n:22 items) and third part of the questionnaire 
assessed the barriers in practicing better management of 
asthma (n = 25 items). A five-point Likert-type scale (from 
strongly agree to strongly disagree) was used to elicit the 
perception of the pharmacists towards management and 
treatment outcomes of asthma. The maximum score for 
perceived practice was 110. Respondents who scored more 
than 66 points were considered as having good perceived 
practice. The said score makes 60% of the total score 
(66/110x100=60%). The choice of 60% was made based 
on previous studies where the said percentage values were 
considered as good perceived practice. Content and face 
validation was done by a group of senior pharmacists in 
academia and practicing community pharmacists. The 
questionnaire was pretested on a convenient sample of 
33 pharmacists (not included in the final sample) which 
were not the targeted population. Rasch measurement 
model was applied to confirm the reliability of the 
questionnaire with Real Item Reliability (Real RMSE) of 
r=0.79. The Rasch measurement model was also applied 
on the real data in order to reconfirm the reliability of 
the questionnaire whereby Real Item Reliability (Real 
RMSE) of r=0.84 was obtained. The questionnaire was 
endorsed as valid and reliable for the research among 
health professionals mainly pharmacists to assess the 
perceived practice and barriers of asthma management 
among community pharmacists. 
Data analysis
All data were analyzed using Statistical Package for 
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Social Science (SPSS Inc., Chicago, Ill., USA) version 
19. The independent t-test and one-way ANOVA with 
post hoc Tukey HSD (honestly significant difference: a 
post hoc analysis used for multiple comparisons in order 
to detect whether or not differences between pair-wise 
groups exists) were used where appropriate. The level of 
statistical significance was set at p < 0.05. 
RESULTS
This study successfully recruited 150 urban 
community pharmacists in Selangor, Malaysia, hence 
fulfilled the sample size requirement. 
Socio-demographic data and asthma professional 
practice
The socio-demographic characteristics of the 
participants are presented in Table I. The mean (±SD) 
age of the respondents was 31.53 SD ± 4.93. There were 
55 (36.7%) male and 95 (63.3%) female respondents. On 
ethnicity basis, the number of Malay respondents were 
89 (59.3%), the Chinese 51 (34.0%) and the Indian 10 
(6.7%)). The majority of respondents had a bachelor’s 
degree (134 (89.3%)). The mean (±SD) number of 
practicing years at community (primary care) level was 
4.76 (±2.62). Only 6 pharmacists were current smoker and 
1 pharmacist had asthma.
Out of 150 retail pharmacies 124 (82.7%) were 
chain and 26 (17.3%) independent, with 94 (62.7%) 
located in shopping malls and 56 (37.3%) in shopping 
strips. The mean number (±SD) of working hours of the 
pharmacists in the community pharmacies was 32.45 
(±11.3) per week. There were 147 (98.7%) pharmacists 
who were aware, and 145 (96.7%) knowledgeable about 
the contents of the asthma guidelines used in the country. 
Malaysia’s own asthma care clinical practice guidelines 
(CPG) were used by 98(65.33%) pharmacists while Global 
Initiative for Asthma (GINA) guidelines was used by 52 
(34.67%) pharmacists. The mean number (±SD) of asthma 
prescriptions was 12.38 (±3.23) out of all prescriptions 
33.87 (±9.16) received by the pharmacists per week. In 
addition, 5.21 (±0.95) out of total patients (23.07(±3.48)) 
were asthmatic patients seen per week. The mean time 
(±SD) of 5.59(±1.47) minutes spent on each asthma 
prescription. About 27.59 (±4.12) asthma drugs were 
dispensed per week. 
An average (±SD) of 4.68 (±0.78) minutes spent 
by the pharmacists to educate the asthmatic patients with 
the help of nebulizers (5 (3.3%)), booklets (100 (66.7%)), 
spacer devices (16 (10.7%)), peak expiratory flow meters 
(5 (3.3%)) and metered dose inhalers (24 (16.0%)). 
All pharmacists were providing asthma educational 
material like pamphlets (103 (68.7%)), brochures (44 
(29.3%)), (booklets 3(2.0%)) during counseling session. 
All pharmacists used to demonstrate how to use an 
inhaler by using patient’s inhaler (106 (70.7%)), using 
placebo inhaler (71 (47.7%)) and verbally 135 (90%). All 
pharmacists referred asthmatic patients to the physician 
(108 (72.0%)) and pulmonologist (42 (28%)). There were 
140 (93.3%) pharmacists who agreed that patients with 
asthma should receive asthma counseling and education 
at every opportunity, while 144 (96%) pharmacists 
agreed that patients should also receive counseling from 
physicians. Most of the respondents (136 (90.7%)) agreed 
that pharmacists are just as effective as physicians in 
providing asthma counselling and education.
Many pharmacists (124 (82.7%)) were aware of 
asthmatic patients presented at the pharmacy between 
acute episodes of asthma. All pharmacists always asked 
the asthma patient to consult a doctor and obtain a 
prescription whenever a prescription is needed. For inhaled 
corticosteroids (150 (100%)), injectible corticosteroids 
(150 (100%)), oral corticosteroids (150(100%)), 
combination inhaled beta2 agonist+corticosteroids (143 
(95.3%)), leukotriene modifiers (137 (91.3%)) and 
TABLE I - Socio-demographic data of study participants
Demographic 
Parameters Groups N (%)
Age
21-30 69 (46.0
31-40 75 (50.0)
>40 6 (4.0 )
Mean= 31.53, SD= ±4.93, Min.=23, 
Max=43
Gender
Male 55 (36.7 )
Female 95 (63.3 )
Ethnicity
Malay 89 (59.3)
Chinese 51 (34.0)
Indian 10 (6.7)
Pharmacy 
Education Level
Bachelor of 
Pharmacy 134 (89.3)
Master of Pharmacy 16 (10.7)
Number of 
Practicing year(s) at 
community level
1-5 99 (66.0)
6-10 48 (32.0)
>10 3 (2.0)
Mean= 4.76, SD= ±2.62, Min=1, 
Max=11
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cromones (147 (98.0%)), pharmacists used to request 
a prescription prior dispensing to asthmatic patients. 
The majority of pharmacists (147(98.0%)) already 
provided treatment during an asthma attack at the 
pharmacy and afer that all pharmacists used to advice the 
patients to consult the physician. Pharmacists suggested 
providing patients with acute episodes of asthma with 
inhaled beta2 agonist (short acting) (144(96.0%)), oral 
beta2 agonist (138(92.0%)), inhaled corticosteroids 
(138(92.0%)), injectable corticosteroids (49 (32.7%)) 
and oral corticosteroids (133(88.7%)). They proposed 
inhaled beta2 agonist (long acting) (148 (98.7%)), oral 
beta2 agonist (148(98.7%)), inhaled corticosteroids 
(146(97.3%)), injectable corticosteroids (139 (92.7%)), 
oral corticosteroids (149 (99.3%)), inhaled combination 
of beta2 agonist+corticosteroids (135(90%)), leukotriene 
modifiers (143 (95.3%)) and cromones (139 (92.7%)) for 
long-term treatment. Almost all (145 (96.7%)) pharmacists 
did not think that patients should continue a long-term 
treatment after an acute episode. All respondents agreed 
to participate in professional education related to the 
management of asthma. Also, 120 (80%) of pharmacists 
agreed to participate in seminars, courses, conferences and 
workshops while 11 (7.3%) and 9 (6%) pharmacists agreed 
to get asthma related professional education via patient 
care audits and written clinical materials or guidelines, 
respectively.
Pharmacists’ perceived perceptions of their role 
in asthma management
The overall mean (±SD) score of the perceived 
practice of asthma was 99.29 (±4.58). About 82.7% (n = 
124) of the participants strongly believed that pharmacists 
should counsel the patients about issues related to asthma 
to the elder age. Almost two thirds of participants (123 
(82.0%)) also strongly believed that pharmacists should 
counsel the patients about the frequency of use of reliever 
inhaler. Most pharmacists (121 (80.7%)) strongly agreed 
that patients should know about the general definition of 
asthma. 
One third of pharmacists (50 (33.3%)) had neutral 
opinion about the counseling of inhaler technique on a 
regular basis whereas 39 (26.0%) pharmacists had neutral 
opinion about counseling on self-monitoring of asthma (by 
symptoms or peak flow measurements).
One way ANOVA was applied to compare the mean 
differences of perceived practice score among different 
groups of age, ethnicity and number of practicing years 
at community level and independent sample t-test was 
applied to compare the mean differences among gender 
and pharmacy education level of urban community 
pharmacists presented in Table III. There was a significant 
difference between the pharmacy education level and 
perceived practice of asthma management while there was 
no significant difference between age, gender, ethnicity, 
number of practicing year and perceived practice of 
asthma management among respective respondents.
Barriers towards asthma management
The four major barriers identified by over 95% of 
pharmacists impacting on their ability to provide specific 
asthma services included pharmacist’s lack of time, 
patients’ perception that they are already well cared by 
the doctor, lack of time and asthma knowledge among 
pharmacists. Most of the barriers were related to ‘patient 
factors’ that included Patient’s lack of asthma knowledge 
and cost of the drugs. These barriers were identified as 
the potential hindrances towards asthma management as 
identified by pharmacists presented in Tables IV and V.
DISCUSSION
This current study showed that pharmacists had 
good perceived practice of asthma with the mean (±SD) 
score of 99.29 (±4.58). Pharmacists perceived their roles 
in asthma management along three major dimensions: 
‘patient’s self-management’, ‘medication use’ and ‘asthma 
control’. Similar type of studies had been conducted over 
the last decade in assessing the pharmacist’s role in the 
management of asthma (Garcia-Cardenas et al., 2016). 
Some other studies of the similar type were also conducted 
to explore the pharmacist’s perceptions about their roles 
in the asthma management (Saini, Krass, Armour, 2004; 
Schulz et al., 2001) however, this is the first study that 
demonstrated the perceived practice and barriers toward 
asthma management among community pharmacists 
working in the urban area in Selangor, Malaysia. It was 
observed that guidelines for managing asthma patients 
could not define the optimal role of community pharmacists 
for an average community pharmacist working in Selangor. 
Therefore pharmacists own perceptions about their role 
could be of prime importance for future development. The 
similar findings were also observed in a study conducted in 
rural and metropolitan area of New South Wales, Australia 
(Kritikos, Reddel, Bosnic-Anticevic, 2010). Almost two 
thirds (127 (84.6%)) of the pharmacists agreed that they 
should counsel the patient about self-monitoring of asthma 
control and asthma self-management. Many pharmacists 
believed that patients should know about the difference 
between the preventer and reliever inhaler. With regard 
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to the adherence with medication 108 (72%) pharmacists 
had the perception to counsel the patient about adherence 
with reliever medication while 135 (90%) pharmacists 
were of the opinion to counsel the patients about 
adherence with preventer medication. Most pharmacists 
had the perception to counsel the patients about inhaler 
technique when patients received the first prescription of 
inhaler (135 (90%)), handling and cleaning of spacer and 
nebulizer when required (137 (91.4%)), advantages and 
disadvantages of various inhalational delivery systems 
(122 (81.4%)), interactions of drugs with asthma and 
asthma medication (145 (96.7%)) and the danger of non-
prescribed self-medication including certain traditional 
medicines (140 (93.3%)). The similar sort of results were 
TABLE II - Perceived practice about the asthma management (n = 150). The roles of the pharmacists should include counseling 
asthmatic patients about
Item 
number Item
Strongly 
disagree 
n (%)
Disagree 
n (%)
No comment 
n (%)
Agree 
n (%)
Strongly 
Agree 
n (%)
1 General definition of asthma 01 (0.7) 06 (4.0) 22 (14.7) 121 (80.7)
2 Trigger factors and avoidance strategies 31 (20.7) 36 (24.0) 83 (55.3)
3 Patient’s current level of asthma control 
(symptoms) and severity.
03 (2.0) 12 (8.0) 44 (29.3) 91 (60.7)
4 Patient self-monitoring of asthma control (by 
symptoms or peak flow measurements).
03 (2.0) 39 (26.0) 21 (14.0) 87 (58.0)
5 Action plan ownership of asthma 25 (16.7) 25 (16.7) 100 (66.7)
6
Asthma self-management by the patient (i.e. 
recognizing when and knowing how to take 
action when asthma gets worse) (early warning 
signs).
15 (10.0) 33 (22.0) 102 (68.0)
7 Differences between reliever and preventer 
(controller) medications.
23 (15.3) 32 (21.3) 95 (63.3)
8 Frequency of reliever inhaler use. 01 (0.7) 04 (2.7) 22 (14.7) 123 (82.0)
9 Overuse of reliever medication. 01 (0.3) 37 (24.7) 23 (15.3) 88 (58.7)
10 Adherence with preventer (controller) medication. 15 (10.0) 21 (14.0) 114 (76.0)
11 Adherence with reliever medication. 42 (28.0) 34 (22.7) 74 (49.3)
12 Inhaler technique when first prescribed the inhaler. 02 (1.3) 13 (8.7) 36 (24.0) 99 (86.0)
13 Inhaler technique on a regular basis. 5 (3.3) 50 (33.3) 16 (10.7) 79 (52.7)
14 Handling and cleaning of spacer and nebulizer when required. 13 (8.7) 25 (16.7) 112 (74.7)
15 Purpose and potential side effects of the asthma drugs. 3 (2.0) 30 (20.0) 27 (18.0) 90 (60.0)
16 Interactions of drugs with asthma and asthma medication. 05 (3.3) 25 (16.7) 120 (80.0)
17 The danger of non-prescribed self-medication including certain traditional medicines. 10 (6.7) 30 (20.0) 110 (73.3)
18 Smoking cessation (if relevant). 07 (4.7) 23 (15.3) 120 (80.0)
19 Issues associated with children with asthma. 7 (4.7) 38 (25.3) 28 (18.7) 77 (51.3)
20 Issues associated with asthma in the elderly. 4 (2.7) 10 (6.7) 12 (8.0) 124 (82.7)
21 Advantages and disadvantages of various inhalational delivery systems. 10 (6.7) 18 (12.0) 16 (10.7) 106 (70.7)
22 Immunotherapy for asthma 16 (10.7) 15 (10.0) 119 (79.3)
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TABLE III - Distribution of perceived practice of asthma according to socio-demographic variables
Variables Groups N Mean + SD (df) P value
Age
21-30 69 99.23 ± 4.90
31-40 75 99.21 ± 4.37 149 .099
>40 6 100.83 ± 3.37
Gender
Male 55 99.50 ± 4.19 148 .181
Female 95 99.15 ± 4.79
Ethnicity
Malay 89 98.90 ± 4.39
Chinese 51 99.98 ± 4.98 149 .406
Indian 10 99.20 ± 3.91
Pharmacy education 
level
Bachelor of Pharmacy 134 97.32 ± 4.70 148 .035
Master of Pharmacy 16 99.93 ± 3.43
Number of practicing 
year(s) at community 
level
1-5 99 99.62 ± 5.06
6-10 48 98.70 ± 3.42 149 .397
>10 3 97.33 ± 3.21
TABLE IV - Response of pharmacists towards barriers in asthma management Indicate to what extent you feel each of the following 
factor impact on the pharmacist’s ability to provide specific asthma counseling or services
Item 
number Item
Strongly 
disagree 
n (%)
Disagree 
n (%)
No comment 
n (%)
Agree 
n (%)
Strongly 
Agree 
n (%)
1 Lack of time by the pharmacist 4 (2.7) 10 (6.7) 12 (8.0) 124 (82.7)
2 Lack of time by the patient. 7 (4.7) 38 (25.3) 28 (18.7) 77 (51.3)
3 Pharmacists’ perception that it is not their roles. 10 (6.7) 18 (12.0) 16 (10.7) 106 (70.7)
4 Patient’s perception that it is not the pharmacist’s roles. 16 (10.7) 15 (10.0) 119 (79.3)
5 Language barriers. 13 (8.7) 25 (16.7) 112 (74.7)
6 Patient’s health beliefs. 10 (6.7) 50 (33.3) 58 (38.6) 32 (21.3)
7 Pharmacist’s lack of asthma knowledge. 07 (4.7) 28 (18.7) 115 (76.7)
8 Patient’s lack of asthma knowledge. 04 (2.7) 10 (6.7) 136 (90.7)
9 Patients’ perception that they are already well cared for by the doctor. 19 (12.7) 14 (9.3) 117 (78.0)
10 Conflict between professional and commercial interests 3 (2.0) 08 (5.3) 18 (12.0) 121 (80.7)
11 Trying not to “overstep” the role of the doctor. 7 (4.7) 38 (25.3) 28 (18.7) 77 (51.3)
12 No financial incentive. 10 (6.7) 86 (57.3) 32 (21.3) 22 (14.7)
13 Difficulty to know patient’s need. 10 (6.7) 18 (12.0) 17 (11.3) 105 (70.0)
14
Lack of appropriate educational materials 
available to use including inhalational devices 
and peak flow meter.
16 (10.7) 15 (10.0) 119 (79.3)
15 Cost of appropriate educational materials to patients is prohibitive. 13 (8.7) 25 (16.7) 112 (74.7)
16 Patient presenting without a prescription. 46(30.7) 34 (22.7) 53 (35.3) 17 (11.3)
17 Cost of the drugs. 13 (8.7) 33(22.0) 104 (69.3)
18 Lack of counseling space. 1 (0.7) 21 (14.0) 13 (18.7) 115 (76.7)
19 Lack of support staff. 6 (4.0) 07 (4.7) 26 (17.3) 111 (74.0)
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also observed in a study conducted in Belgium; where 
community pharmacists intervention, like counseling 
and educating patients about different inhalation, 
nebulization and relieving techniques and instruments, 
improved the health outcomes significantly (Mehuys et 
al., 2008; Lemmens, Nieboer, Huijsman, 2009). Almost all 
pharmacists (143 (95.3%)) had the perception to counsel 
the patients about smoking cessation when applicable. 
This was mainly important because smoking cessation 
could improve the lung function and decrease the severity 
and symptoms of the disease significantly (Chaudhuri et 
al., 2006). 
Comparing the current study with some of the other 
studies on asthma management, a significant difference 
between the pharmacy education level and perceived 
practice of asthma management was noted. The difference 
demonstrated that highly qualified respondents had 
good perceived practice as compared to less qualified 
respondents while there was no significant difference 
between age, gender, ethnicity, number of practicing year 
and perceived practice of asthma management among 
respective respondents (Mehuys et al., 2008).
In this study, pharmacists identified most important 
and common barriers to asthma counseling including both 
pharmacists and patients related factors. For pharmacists 
related factors, most of the participants (85%) agreed 
that lack of time, lack of knowledge, lack of appropriate 
educational materials, lack of counseling space and 
‘pharmacists’ perception that “it is not their role” are the 
most important barriers in asthma counseling. Lack of 
time by the patient, patients’ perception that “it is not the 
pharmacist’s role”, cost of drugs and no financial incentive 
were the most commonly observed patients related barrier 
by the pharmacists regarding asthma counseling. Similar 
types of barriers were identified by Australian community 
pharmacists (Kritikos, Reddel, Bosnic-Anticevich, 2010).
Furthermore, all enrolled pharmacists agreed to 
participate in professional education related to asthma 
management programs. Among these community 
pharmacists, 120 (80%) pharmacists recommended 
seminar/ workshop/course or conference as a medium 
for this purpose, while rest of them were divided in their 
recommendations between written clinical material/
guideline (9(0.6%)) and patient care audits 11(7.3%). 
So there is a need to design an educational asthma care 
program for the local community pharmacists keeping 
in view the GINA guidelines to improve pharmacist’s 
professional capabilities which will ultimately lead to 
increase patient care outcomes in the future (Armour et 
al., 2007). 
Limitations
This study was conducted only among urban 
community pharmacists in one state of Malaysia (i.e. 
Selangor), therefore the finding of this study cannot be 
generalized to the whole population of urban community 
pharmacists in Malaysia. The design of this study was 
cross-sectional, so the findings of the study could be 
considered only as correlation not causal. Although the 
cross sectional study design does not permit strong causal 
inferences yet can be very useful for describing variables 
and their distribution patterns. The strength of this study 
was the high response rate in recruited respondents.
CONCLUSION
Overal l ,  urban community pharmacists  in 
Selangor, Malaysia, possessed good perception on 
better management of asthma. Community pharmacists 
perceived a three-dimensional role in asthma care. This 
study also highlighted both pharmacist- and patient-
related barriers towards asthma counseling. Most of 
the barriers were related to ‘patient factors’. The major 
barriers towards asthma management observed were 
lack of pharmacist’s time, patients’ perceptions about the 
TABLE V - Lack of Confidence or Skills
Item 
number Items
Strongly 
disagree 
n (%)
Disagree 
n (%)
No comment 
n (%)
Agree 
n (%)
Strongly 
Agree 
n (%)
1 Asthma medication counseling 6 (4.0) 46 (30.7) 26 (17.3) 72 (48.0)
2 Asthma adherence counseling 4 (2.7) 10 (6.7) 12 (8.0) 124 (82.7)
3 Asthma self-management counseling 12 (8.0) 40 (26.7) 98 (65.3)
4 Asthma triggers factor counseling. 11 (7.3) 29 (19.3) 110 (73.3)
5 Reviewing and counseling about asthma control 11 (7.3) 32 (21.3) 107 (71.3)
6 Asthma monitoring 07 (4.7) 44 (29.3) 89 (66.0)
W. Akram, N. Ijaz, H. Ahmad, M. Jamshaid, N. E. Ismail
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physician’s care, lack of patient’s time, knowledge and 
awareness about asthma and cost of the drugs as identified 
by pharmacists. The Malaysian participants’ experiences 
are similar to those reported in previous studies conducted 
in other countries, but some other perceptions and barriers 
peculiar to the Malaysian context have been identified. 
Future studies should explore more barriers and find out 
the ways to solve these highlighted barriers.
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